Although one clinical trial suggested the superiority of fingolimod to IFN-β in its efficacy [3], cardiovascular adverse events, infections, macular edema, and progressive multifocal leukoencephalopathy (PML) have raised concerns during the treatment with fingolimod [4]. The gene discussed is IFNB1; the disease is progressive multifocal leukoencephalopathy.